Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2022

View Archived Issues

Novel ER modulator daidzein analogues confer antitumoral effect in prostate cancer

Machine learning approach speeds resistance identification

BeiGene discloses non-receptor tyrosine-protein kinase TYK2 inhibitors

New GLP-1 receptor agonists identified at Guangzhou Henovcom Bioscience

Celgene presents new cereblon-binding PROTACs

New glucocorticoid receptor antagonists discovered at Corcept Therapeutics

Viral replication inhibitors patented by Gilead

New 3,5-diaryl-substituted pyrazoles inhibit prostate cancer cell growth

Targeting IP3R-mediated Ca2+ homeostasis in adipocytes as strategy against metabolic disease

AstraZeneca and Scorpion collaborate on therapeutics against transcription factors for cancer

Intranasal influenza-based boost vaccination for preventing SARS-CoV-2 infection

Vir expands partnership with Gates Foundation in HIV and malaria

Preclinical data confirm anticancer activity of two lead compounds in Captor's CT-01 program in HCC

Novel genes identified with risk of obsessive-compulsive disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...